Last reviewed 2026-04-20 · How we verify

ROCURONIUM BROMIDE

At a glance

Approved indications

• Rapid sequence and routine tracheal intubation
• Skeletal muscle relaxation during surgery or mechanical ventilation

Common side effects

• Transient hypotension
• Hypertension
• Tachycardia
• Nausea
• Vomiting
• Asthma (bronchospasm, wheezing, or rhonchi)
• Hiccup
• Rash
• Injection site edema
• Pruritus
• Arrhythmia
• Abnormal electrocardiogram

Key clinical trials

• The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
• Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
• Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
• Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
• Deep Versus Moderate Neuromuscular Blocking (NA)
• Effect of Neuromuscular Block Depth on Driving Pressure and Postoperative Respiratory Events in Abdominal Surgeries (NA)
• Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults (PHASE2)
• A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ROCURONIUM BROMIDE CI brief — competitive landscape report
• ROCURONIUM BROMIDE updates RSS · CI watch RSS